In clinical trials, in a range of indications including Allergic Rhinitis (AR) and Chronic Idiopathic Urticaria (CIU), the most frequently reported adverse effects were headache, somnolence, fatigue and dry mouth, gastrointestinal disorders such as nausea, gastritis, and also allergic symptoms like rash.
At the recommended dose, loratadine had no clinically significant sedative properties.
In addition, other adverse reactions reported very rarely during the post-marketing period are listed in the following table in order of decreasing seriousness of loratadine: See table.
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
View ADR Monitoring Form